PD-1 / PD-L1 monoclonal antibody — Competitive Intelligence Brief

PD-1 / PD-L1 monoclonal antibody (PD-1 / PD-L1 monoclonal antibody) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1/PD-L1 inhibitor. Area: Oncology.

marketed PD-1/PD-L1 inhibitor PD-1 and/or PD-L1 Oncology Small molecule

Target snapshot

PD-1 / PD-L1 monoclonal antibody (PD-1 / PD-L1 monoclonal antibody) — Cancer Institute and Hospital, Chinese Academy of Medical Sciences. This monoclonal antibody blocks the PD-1/PD-L1 immune checkpoint pathway to restore anti-tumor T cell activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PD-1 / PD-L1 monoclonal antibody TARGET	PD-1 / PD-L1 monoclonal antibody	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	marketed	PD-1/PD-L1 inhibitor	PD-1 and/or PD-L1
PD1/PDL1 inhibitor	PD1/PDL1 inhibitor	Second Affiliated Hospital of Guangzhou Medical University	phase 3	PD-1/PD-L1 inhibitor	PD-1 and/or PD-L1
Full course of PD-1/PD-L1 blockades	Full course of PD-1/PD-L1 blockades	Sun Yat-sen University	phase 3	PD-1/PD-L1 inhibitor	PD-1 and PD-L1
Tiragolumab and atezolizumab	Tiragolumab and atezolizumab	University Medical Center Groningen	phase 3	PD-1/PD-L1 inhibitor	TIGIT, PD-L1
Pembrolizumab/Vibostolimab Co-Formulation	Pembrolizumab/Vibostolimab Co-Formulation	Merck Sharp & Dohme LLC	phase 3	PD-1/PD-L1 inhibitor	PD-1/PD-L1
MAZ-101association	MAZ-101association	EMS	phase 3	PD-1/PD-L1 inhibitor	PD-1/PD-L1
TQB3616 capsule	TQB3616 capsule	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	PD-1/PD-L1 inhibitor	PD-1/PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1/PD-L1 inhibitor class)

1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 3 drugs in this class
2. AstraZeneca · 2 drugs in this class
3. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
4. Hanlim Pharm. Co., Ltd. · 1 drug in this class
5. EMD Serono · 1 drug in this class
6. EMS · 1 drug in this class
7. Fujian Cancer Hospital · 1 drug in this class
8. Elixiron Immunotherapeutics (Hong Kong) Ltd. · 1 drug in this class
9. Cellvax Therapeutics Inc · 1 drug in this class
10. Anhui Shi, MD · 1 drug in this class